Alternate Day Fasting for the Improvement of Side Effects and Quality of Life in Patients Undergoing Chemotherapy for Newly Diagnosed or Recurrent Endometrial, Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAST Trial

Inclusion Criteria

• Female; ≥ 18 years of age
• Confirmed or high suspicion for new or recurrent diagnosis of endometrial, ovarian, fallopian tube or primary peritoneal cancer, and are able and expecting to undergo chemotherapy for treatment of disease, as determined by their treating physician
• Fluent in spoken and written English
• Own a smart phone
• Have access to the internet to complete surveys
• Eastern Cooperative Oncology Group (ECOG) status of 0 or 1
• Willingness to sign informed consent form

Exclusion Criteria

• Patients who are not planning to undergo chemotherapy at Northwestern Medicine
• Body mass index (BMI) of < 18.5 or BMI of 50+, or those with a diagnosed eating disorder. Patients who take medications for blood glucose regulation (e.g. insulin), and/or require treatment with diet dependent anticoagulants (e.g. Warfarin) will be excluded
• Patients who have been diagnosed with medication-dependent diabetes or any condition that may preclude ability to tolerate a short-term fast will be excluded. Conditions meeting these criteria will be determined at the discretion of the treating physician
• Patients who take medications where conditions may be influenced in the presence of fasting (e.g. hypertension, electrolyte abnormalities, migraines) will be monitored by their treating physician for any necessary adjustments in these medications
• Patients whose oncologist has not provided clearance for their participation
• Unable or unwilling to follow a diet regimen or participate in ketone measurements
• ECOG status greater than 1
• Patients who have undergone prior systemic therapy to treat a malignancy in the last 2 years